Navigation/Menü: Links auf weitere Seiten dieser Website
|Änderungen des kognitiven Leistungsvermögens nach induzierter Physikalischer Urtikaria und Gabe von Ebastin|
|Main title||Änderungen des kognitiven Leistungsvermögens nach induzierter Physikalischer Urtikaria und Gabe von Ebastin|
|Title variations||Changes in cognitive performance after induced physical urticaria and administration of Ebastine|
Place of birth: Berlin
|1. Referee||Prof. Dr. med. M. Maurer|
|Further Referee(s)||Prof. Dr. med. J. Grabbe; Priv.-Doz. Dr. med. P. Staubach-Renz|
|Keywords||Urticaria, itching, antihistamines, cognitive performance, physical urticaria, dermographic urticartia, cold urticaria|
|Classification (DDC)||610 Medical sciences; Medicine|
|Summary||Background: Urticaria is a common skin condition with a wide range of subtypes. It is characterized by the rapid appearance of wheals and itching or burning sensation. The physical urticarias are chronic conditions triggered by their respective namesake physical factors. Their pathogenesis remains mostly unclear, but it is known that mastcell degranulation releases histamine and other mediators, thus causing the wheal-and-flare reaction. The most common forms of physical urticaria are dermographic urticaria (DU) - shearing forces on the skin result in weals and itching - and Acquired cold urticaria (ACU) - a skin condition, in which exposure to cold results in wheals and itching. Both have a profound impact on patient quality of life. Secondgeneration antihistamines are recommended as the first-line treatment.
Aim: The objective of this pilot study was to assess how urticaria symptoms affected cognitive performance and mood as known in allergic rhinitis. And if a single dose of 20 mg of the second-generation antihistamine Ebastine is effective in protecting urticaria patients from this impairment of performance.
Methods: This pilot-study was designed as a double-blind, crossover, placebocontrolled, trial including 29 adults. After having received Placebo or 20 mg Ebastine, cognitive performance and mood were assessed before and after ACU and DU symptoms were experimentally provoced on two areas of the forearms.
Efficacy was assessed by rating weals, erythema, pruritus and burning after provocation.
Results: Neither urticaria symptoms nor the Ebastine treatment had negative impact on any of the parameters of cognitive performance or mood but Ebastine dramatically reduced the number of patients who experienced wheals, pruritus, and burning after provocation.
Conclusion: This pilot study suggests that urticaria symptoms had no negative impact on cognitive performance or mood and that Ebastine is safe and effective in preventing the symptoms of ACU and DU.
PDF-Datei von FUDISS_thesis_000000022424
|FU Department||Department of Medicine - Charité - University Medicine Berlin|
|Year of publication||2011|
|Document type||Doctoral thesis|
|Date of defense||2011-06-05|
|Created at||2011-05-04 : 07:09:56|
|Last changed||2011-05-27 : 08:27:31|